Patient-Specific Implants

The claim

India is one of the few markets where patient-specific implants can be sold at mass-market prices rather than luxury ones — and the winner will not be the company with the best printer. It will be the company that owns the workflow between the CT scan and the operating table.

I spent my undergraduate years characterising 3D printing processes at IIT Guwahati, so I want to be precise about what has and has not changed. The hardware is commoditising. Metal additive manufacturing in titanium and polymer printing in PEEK are now well-understood, buyable, and no longer a source of durable advantage. What is scarce is everything wrapped around them.

Why India, and why now

Three things arrived at roughly the same time.

Demand that standard implants serve badly. India carries an enormous burden of trauma from road accidents, a large and undertreated amputee population, and a fast-growing volume of joint replacement and oncological reconstruction. Standard off-the-shelf implants are sized against Western anthropometry. A meaningful share of Indian patients — particularly women, and particularly in knee and hip arthroplasty — are fitted with geometry that was never designed for their bone. Surgeons compensate intraoperatively. That compensation is exactly what a patient-specific implant removes.

A cost base that makes customisation economically ordinary. In the US or EU, the engineering labour required to segment a scan, design an implant, validate it and produce a surgical guide makes patient-specific devices a premium product. In India that same labour is cheap and abundant — and it is mechanical and biomedical engineering talent, which India produces in volume and largely exports. This is the arbitrage. Not the printing. The design hours.

A regulatory path that now exists. Medical devices in India moved under a defined CDSCO framework with risk-based classification, which is slower and more expensive than the informal era that preceded it — and that is the point. A real approval process is a barrier that rewards whoever clears it first and builds the quality system to stay cleared.

Where the value actually sits

The naive version of this business buys printers and sells implants. It gets competed to zero, because printers are purchasable and titanium powder is a commodity.

The defensible version sells turnaround time and surgeon confidence. Concretely, it owns:

• Segmentation and design throughput. Turning a DICOM scan into a validated, printable, patient-specific design in days rather than weeks. This is a software-plus-services problem, and it is where accumulated case volume compounds into speed.
• The regulatory file. A quality management system, biocompatibility and mechanical validation, and a clean CDSCO approval history. This is slow, unglamorous, and the single most under-priced asset in the category.
• The surgeon relationship. Implants are not bought by hospitals in any meaningful sense. They are specified by surgeons, one at a time, and surgeons switch on trust built over cases — including planning support and printed anatomical models before the operation.
• Case data. Every completed case is a labelled example of anatomy, design decision and outcome. Enough of them and the design step starts to automate, which collapses cost per case in a way a competitor without the volume cannot follow.

The moat is a flywheel: more cases produce faster design, faster design wins more surgeons, more surgeons produce more cases. The printer is a line item inside it.

The model I would want to back

Start narrow. One anatomical wedge where custom geometry is clearly superior and the surgeon already knows it — cranio-maxillofacial reconstruction and complex orthopaedic oncology are the obvious candidates, because there the off-the-shelf option is genuinely poor and price sensitivity is lowest.

Win a concentrated set of high-volume centres rather than broad shallow coverage. Sell the planning workflow and the anatomical model first, because those enter the hospital at low regulatory friction and establish the relationship before the implant does. Then move down the acuity curve into higher-volume, lower-complexity procedures once the design cost per case has fallen enough to support it.

Exports are the second act, not the first. An Indian design-and-manufacture base serving Southeast Asia, Africa and the Gulf is a genuinely large business — but only on top of a domestic quality record that makes the claim credible.

What kills it

• Reimbursement. A large share of Indian orthopaedic volume runs through price-capped and government-scheme channels. If patient-specific implants cannot be priced above the cap, the addressable market shrinks to self-pay and private insurance, which is a real business but a much smaller one.
• Turnaround time. Trauma does not wait. Any workflow that cannot deliver inside the clinical window is confined to elective and planned reconstruction. This is the operational constraint that decides the category, and it is where I would spend the most diligence.
• Incumbent reach. Global orthopaedic majors have the distribution and the surgeon relationships already. If they decide to bundle a custom offering into existing contracts, a standalone player needs a genuine speed or cost advantage, not a marginal one.
• Founder mismatch. This needs a team that is simultaneously credible in an operating theatre and competent at a quality management system. That pairing is rare and it is the first thing I would test.

What would change my mind

I would want to see design cost per case falling with volume — if case fifty costs what case five did, there is no flywheel and this is a job shop with good margins. I would want repeat rate at the level of the individual surgeon, not the hospital. And I would want at least one anatomical category where the clinical argument is strong enough that a surgeon would pay the premium out of conviction rather than curiosity.

Absent those, this is precision manufacturing with a healthcare story attached, and it should be valued that way.